Innovent Biologics and Shenogen Pharma Group have signed a collaboration agreement to evaluate the combination therapy of Innovent’s Tyvyt with Shenogen’s SNG1005, in patients with advanced cancer.

Tyvyt is a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody co-developed by Innovent and Eli Lilly and Company in China.

SNG1005, for which Shenogen has full development and commercialisation rights in Greater China, is a conjugate of angiopep-2 and paclitaxel that was licenced by the company from overseas.

Multiple Phase II clinical trials are complete for SNG1005 in the US and its Phase III clinical trial protocol has been approved by the US Food and Drug Administration (FDA).

Shenogen Pharma chairman Dr Kun Meng said: “The combined therapy of immune checkpoint inhibitors and anti-tumour therapeutics has become the standard approach for the development of anti-tumour treatments.

“We are looking forward to close cooperation with Innovent in exploring the potential efficacy of anti-PD-1 inhibitor in combination with SNG1005. We are expecting the underlying synergistic effect in various cancers.”

Tyvyt secured approval for market authorisation from the NMPA in December last year for the treatment of patients with classical Hodgkin’s lymphoma (cHL) that has relapsed or refractory (r/r) after two or more lines of systemic chemotherapy (r/r cHL).

Innovent biologics oncology strategy and medical sciences vice-president and head Dr Hui Zhou said: “SNG1005 is a first-in-class nab-paclitaxel therapeutic in development that can pass through the blood-brain barrier (BBB). We are pleased to cooperate with Shenogen to explore the clinical synergistic efficacy with our PD-1 inhibitor.

“We hope to bring more clinical benefits to patients with advanced carcinomas.”